by Eric Christianson | Aug 12, 2026 | Renal, Urology, and Electrolytes Medication and Disease State Clinical Pearls
Finerenone (Kerendia) is a relatively newer medication for the management of chronic kidney disease (CKD) in patients with type 2 diabetes and heart failure with preserved ejection fraction. In addition to these indications, there was a recent study that showed...
by Eric Christianson | Jul 20, 2025 | Cardiovascular Medication and Disease State Clinical Pearls
Direct oral anticoagulants (DOACs) are widely used in a variety of conditions, including atrial fibrillation, pulmonary embolism, and deep vein thrombosis. Most DOACs are metabolized by CYP3A4 and utilize the P-glycoprotein (P-gp) transporter. Thus, common...
by Eric Christianson | Apr 19, 2023 | Cardiovascular Medication and Disease State Clinical Pearls, Drug Interaction Case Studies and Education For Pharmacists
Beta-blockers are a class of medication that is frequently used for cardiac and cardiovascular purposes. Selectivity and evidence of benefit often guide selection, but one thing that may get overlooked is beta-blocker interactions in relation to CYP enzymes. Not all...
by Eric Christianson | Mar 27, 2022 | Medication and Disease State Clinical Pearls For Pharmacists
COPD is a challenging disease that ultimately leads to a progressive reduction in lung function. Our mainstays of therapy are the bronchodilators like long-acting anticholinergic and long-acting beta-agonists. Roflumilast (podcast) is a unique medication for COPD in...
by Eric Christianson | May 1, 2019 | Drug Interaction Case Studies and Education For Pharmacists
One of the big advantages of newer agents like rivaroxaban is there’s less potential for diet and drug interactions than with warfarin. Now that doesn’t mean that there aren’t any rivaroxaban drug interactions. We have to pay attention to these...
